About Eaglenos
Eaglenos is a company based in Nanjing (China) founded in 2017. Eaglenos has raised $21.2 million across 1 funding round from investors including 3E Bioventures, Huatai Zijin Investment and Innomed Capital. Eaglenos offers products and services including Test Paper Platform and Test Card Platform.
- Headquarter Nanjing, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 南京晶捷生物科技有限公司
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.2 M (USD)
in 1 rounds
-
Latest Funding Round
$21.2 M (USD), Series A
May 29, 2023
-
Investors
3E Bioventures
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eaglenos
Eaglenos offers a comprehensive portfolio of products and services, including Test Paper Platform and Test Card Platform.
Test paper platforms are used for precise detection in health management applications
Test card platforms are employed for point-of-care testing to support personalized health solutions
Funding Insights of Eaglenos
Eaglenos has successfully raised a total of $21.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $21.2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eaglenos
Eaglenos has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include 3E Bioventures, Huatai Zijin Investment and Innomed Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A fund focused on healthcare industry investments is managed.
|
Locked | Locked | Locked | |
|
Innomed Capital is engaged in equity investment fund management.
|
Locked | Locked | Locked | |
|
Private equity investments are managed by the company.
|
Locked | Locked | Locked |
Investor details for Eaglenos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eaglenos
Investment portfolio details for Eaglenos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eaglenos
Detailed financials for Eaglenos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eaglenos Comparisons
Peer comparison for Eaglenos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eaglenos
Detailed competitors of Eaglenos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eaglenos
Complete news archive for Eaglenos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eaglenos
Eaglenos was founded in 2017 and raised its 1st funding round 6 years after it was founded.
Eaglenos is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Eaglenos is a funded company, having raised a total of $21.2M across 1 funding round to date.
Eaglenos was established in 2017 in Nanjing, China, within the medical diagnostics sector. Diagnostic test kits are produced by the company to support healthcare testing needs. Operations are conducted from its base in Nanjing, where manufacturing processes are managed. The companys online presence is maintained through eaglenos.com, facilitating access to product information and distribution channels. Focus is placed on developing kits for various diagnostic purposes, serving regional and international markets.
Eaglenos offers Test Paper Platform and Test Card Platform.
Eaglenos has 4 investors. Key investors include 3E Bioventures, Huatai Zijin Investment, Innomed Capital, and Grand Yangtze.